PD 360324

Drug Profile

PD 360324

Alternative Names: PD-0360324; PD-360,324

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous lupus erythematosus; Pulmonary sarcoidosis; Rheumatoid arthritis

Most Recent Events

  • 06 Nov 2014 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA, Canada & Moldova (IV)
  • 06 Nov 2014 Discontinued - Phase-II for Pulmonary sarcoidosis in USA (IV)
  • 24 Mar 2014 Pfizer terminates phase II trial in Pulmonary sarcoidosis in USA (NCT01732211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top